The Food and Drug Administration's Office of Acquisition and Grant Services intends to issue a sole source award to Jackson Laboratories for multiple strains of severely immuno-compromised mice. Strains include:

Stock #005557 (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ)
Stock #007799 (NOD.Cg-Rag1tm1Mom Il2rgtm1Wjl/SzJ
Stock #000651 (BALB/cJ)

Scientists within FDA performing humanized mouse research have utilized these specific proprietary strains of severely immune compromised mice that are only available from The Jackson Laboratory. Other vendors sell immune compromised mice; however, they are not the same genetic strain and have inherent risk associated with their use. This risk includes the need to repeat all preliminary studies with a new strain of mice, since they are not the biologically the same and would yield different results.
This notice of intent is not a request for competitive proposals. The proposed action is for supplies for which the Government intends to solicit and negotiate with only one source under the authority of 41 U.S.C. 253(c)(1), FAR 6.302-1. The estimated dollar value for this action is not to exceed $150,000. This will result in a contract for a base year with two option years. The projected award date is April 30, 2013.

Interested parties may submit a capability statement by April 16, 2013 for considerations by the agency. Responses must be sent to Juana Quinteros via email at [email protected]. All correspondence must reference FDA-RFP-1113768.